Literature DB >> 14669009

Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias.

Laurent Gouya1, Hervé Puy, Anne-Marie Robreau, Said Lyoumi, Jérome Lamoril, Vasco Da Silva, Bernard Grandchamp, Jean-Charles Deybach.   

Abstract

We have recently demonstrated that in an autosomal dominant porphyria, erythropoietic protoporphyria (EPP), the coinheritance of a ferrochelatase (FECH) gene defect and of a wild-type low-expressed FECH allele is generally involved in the clinical expression of EPP. This mechanism may provide a model for phenotype modulation by minor variations in the expression of the wild-type allele in the other three autosomal dominant porphyrias that exhibit incomplete penetrance: acute intermittent porphyria (AIP), variegata porphyria (VP) and hereditary coproporphyria (HC), which are caused by partial deficiencies of hydroxy-methyl bilane synthase (HMBS), protoporphyrinogen oxidase (PPOX) and coproporphyrinogen oxidase (CPO), respectively. Given the dominant mode of inheritance of EPP, VP, AIP and HC, we first confirmed that the 200 overtly porphyric subjects (55 EPP, 58 AIP, 56 VP; 31 HC) presented a single mutation restricted to one allele (20 novel mutations and 162 known mutations). We then analysed the available single-nucleotide polymorphisms (SNPs) present at high frequencies in the general population and spreading throughout the FECH, HMBS, PPOX and the CPO genes in four case-control association studies. Finally, we explored the functional consequences of polymorphisms on the abundance of wild-type RNA, and used relative allelic mRNA determinations to find out whether low-expressed HMBS, PPOX and the CPO alleles occur in the general population. We confirm that the wild-type low-expressed allele phenomenon is usually operative in the mechanism of variable penetrance in EPP, but conclude that this is not the case in AIP and VP. For HC, the CPO mRNA determinations strongly suggest that normal CPO alleles with low-expression are present, but whether this low-expression of the wild-type allele could modulate the penetrance of a CPO gene defect in HC families remains to be ascertained.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669009     DOI: 10.1007/s00439-003-1059-5

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  23 in total

1.  Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.

Authors:  S Borrego; M E Sáez; A Ruiz; O Gimm; M López-Alonso; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

2.  Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria.

Authors:  U B Rüfenacht; L Gouya; X Schneider-Yin; H Puy; B W Schäfer; R Aquaron; Y Nordmann; E I Minder; J C Deybach
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

3.  Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update.

Authors:  R Rosipal; J Lamoril; H Puy; V Da Silva; L Gouya; F W De Rooij; K Te Velde; Y Nordmann; P Martàsek; J C Deybach
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

5.  Low expression allele alpha LELY of red cell spectrin is associated with mutations in exon 40 (alpha V/41 polymorphism) and intron 45 and with partial skipping of exon 46.

Authors:  R Wilmotte; J Maréchal; L Morlé; F Baklouti; N Philippe; R Kastally; L Kotula; J Delaunay; N Alloisio
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.

Authors:  Anita Gregor; Xiaoye Schneider-Yin; Urszula Szlendak; Albert Wettstein; Agnieszka Lipniacka; Urszula B Rüfenacht; Elisabeth I Minder
Journal:  Hum Mutat       Date:  2002-03       Impact factor: 4.878

Review 7.  Molecular aspects of the inherited porphyrias.

Authors:  S Sassa; A Kappas
Journal:  J Intern Med       Date:  2000-02       Impact factor: 8.989

8.  Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation.

Authors:  L Gouya; H Puy; J Lamoril; V Da Silva; B Grandchamp; Y Nordmann; J C Deybach
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

9.  Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele.

Authors:  L Gouya; J C Deybach; J Lamoril; V Da Silva; C Beaumont; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

Review 10.  Molecular basis of acute intermittent porphyria: mutations and polymorphisms in the human hydroxymethylbilane synthase gene.

Authors:  K H Astrin; R J Desnick
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

View more
  13 in total

1.  The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine.

Authors:  Paolo Ventura; Maria Domenica Cappellini; Emilio Rocchi
Journal:  Intern Emerg Med       Date:  2009-05-29       Impact factor: 3.397

2.  Paralytic ileus and liver failure--an unusual presentation of advanced erythropoietic protoporphyria.

Authors:  Simone Negrini; Gabriele Zoppoli; Maurizio Setti; Maria Domenica Cappellini; Francesco Indiveri
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

Review 3.  Ocular coloboma: a reassessment in the age of molecular neuroscience.

Authors:  C Y Gregory-Evans; M J Williams; S Halford; K Gregory-Evans
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

Review 4.  Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review.

Authors:  Zhang-Biao Long; Yong-Wei Wang; Chen Yang; Gang Liu; Ya-Li Du; Guang-Jun Nie; Yan-Zhong Chang; Bing Han
Journal:  J Zhejiang Univ Sci B       Date:  2016 Oct.       Impact factor: 3.066

5.  Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2.

Authors:  Sharon S Cooperman; Esther G Meyron-Holtz; Hayden Olivierre-Wilson; Manik C Ghosh; Joseph P McConnell; Tracey A Rouault
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 6.  Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis.

Authors:  Achille Iolascon; Luigia De Falco; Carole Beaumont
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

7.  Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria.

Authors:  Victoria E Parera; Rita H Koole; Gardi Minderman; Annie Edixhoven; Maria V Rossetti; Alcira Batlle; Felix W M de Rooij
Journal:  Mol Med       Date:  2009-08-12       Impact factor: 6.354

8.  Product release rather than chelation determines metal specificity for ferrochelatase.

Authors:  Amy E Medlock; Michael Carter; Tamara A Dailey; Harry A Dailey; William N Lanzilotta
Journal:  J Mol Biol       Date:  2009-08-22       Impact factor: 5.469

9.  Clinic and genetic evaluation of variegate porphyria (VP) in a large family from the Balearic Islands.

Authors:  A Bonnin; A Picornell; J Orfila; J A Castro; M M Ramon
Journal:  J Inherit Metab Dis       Date:  2009-02-20       Impact factor: 4.982

10.  Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.

Authors:  Rizwan Hamid; Joy D Cogan; Lora K Hedges; Eric Austin; John A Phillips; John H Newman; James E Loyd
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.